A new approach to market access in China

Sarah Giles of inVentiv Health explores new ways to tackle pharma market access challenges in China. Through their role in effectively managing budgets to improve population-level health outcomes, payers have become the most influential…

Sarah Giles of inVentiv Health explores new ways to tackle pharma market access challenges in China.

Through their role in effectively managing budgets to improve population-level health outcomes, payers have become the most influential gate-keepers of access to medicines in most developed countries across the globe. While this payer role is no different in China, the impressive speed at which new payer systems are developed at a national, provincial and hospital level, and the distinctive way in which these systems are implemented at a local level, leads to a unique payer environment.

In order to be successful in enabling patient access to medicines in China, the evidence-based value story for a given product should be tailored to the specific needs of the Chinese payer system. To help achieve this, the biopharma industry in China should consider adopting the model which is becoming the global gold standard – making market access the central goal of each function of the organization, whereby both internal functions (marketing, medical, HEOR) and external stakeholders work together to define the value of a medicine from multiple perspectives.

The opportunity for the healthcare industry in China….

See on www.pharmaphorum.com

From Pharmaceutical Industry digital vision

Advertisements
Tags:

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s